DDD 3D Systems Corporation

Systemic Bio™, a 3D Systems company (NYSE: DDD), has been named the winner of the prestigious SLAS 2025 Innovation Award. This award recognizes groundbreaking technological advancements poised to drive innovation in laboratory science and automation. The competition featured cutting-edge developments led by distinguished experts from top institutions worldwide.

The award highlights Systemic Bio’s proprietary h-VIOS™ platform, designed to accelerate drug discovery and development using bioprinted human tissues. The Company’s presentation focused on the application of its platform to evaluate the safety of antibody-drug conjugates (ADCs). The technology enables early identification of safety concerns, capturing risks that historically have only been discovered during clinical trials, even after non-human primate studies failed to flag such issues.

“I couldn’t be prouder of our team for winning this award,” said Taci Pereira, CEO of Systemic Bio. “This recognition is a testament to our relentless focus on demonstrating the scientific and translational value of our platform. We remain committed to expanding our capabilities and accelerating adoption to improve drug discovery and development.”

Operating from Houston, Texas, Systemic Bio has the capability to produce thousands of tissue models under an ISO 7 clean room and a Quality Management System (QMS). These models support the Company’s ongoing collaborations with leading pharmaceutical companies to improve preclinical drug testing and reduce late-stage failures.

The SLAS Innovation Award is presented annually at the SLAS International Conference and Exhibition, recognizing the most forward-thinking technological advancements in the field. More information on Systemic Bio’s work can be found at www.systemic.bio.

Forward-Looking StatementsCertain statements made in this release that are not statements of historical or current facts are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Systemic Bio or 3D Systems, as applicable, to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as "believes," "belief," "expects," "may," "will," "estimates," "intends," "anticipates" or "plans" or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions, and current expectations and may include comments as to the beliefs and expectations of Systemic Bio or 3D Systems as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the applicable company. The factors described under the headings "Forward-Looking Statements" and "Risk Factors" in 3D Systems’ periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as of the date of the statement. Neither Systemic Bio nor 3D Systems undertakes any obligation to update or revise any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise, except as required by law.

About Systemic BioSystemic Bio is a biotech company focused on accelerating drug discovery and development with human-relevant data from its proprietary platform of bioprinted vascularized organ models. Founded in 2022 as a wholly-owned company of 3D Systems, Systemic Bio leverages 3D Systems’ breakthrough, production-level bioprinting technology to create extremely precise healthy and diseased tissues using biomaterials and human cells. These proprietary organs-on-chips can be manufactured reproducibly in large quantities, and then perfused with drugs to study the effects on healthy or diseased tissue at the earliest stages of pharmaceutical drug development. These systems are multimodal and can be used to generate large datasets leveraged with machine learning to generate human-relevant therapeutic insights. More information on the company is available at www.systemic.bio.

About 3D Systems More than 35 years ago, 3D Systems brought the innovation of 3D printing to the manufacturing industry. Today, as the leading additive manufacturing solutions partner, we bring innovation, performance, and reliability to every interaction - empowering our customers to create products and business models never before possible. Thanks to our unique offering of hardware, software, materials, and services, each application-specific solution is powered by the expertise of our application engineers who collaborate with customers to transform how they deliver their products and services. 3D Systems’ solutions address a variety of advanced applications in healthcare and industrial markets such as medical and dental, aerospace & defense, automotive, and durable goods. More information on the company is available at www.3dsystems.com.

Investor Contact: investor.relations@3dsystems.comMedia Contact: press@systemic.bio